The Fort Worth Press - Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025

USD -
AED 3.672503
AFN 64.999811
ALL 82.324126
AMD 360.540277
ANG 1.790403
AOA 918.000169
ARS 1544.939993
AUD 1.47493
AWG 1.8
AZN 1.698924
BAM 1.769883
BBD 2.014669
BDT 124.715381
BGN 1.77347
BHD 0.378283
BIF 3011.021908
BMD 1
BND 1.291151
BOB 11.678099
BRL 5.666297
BSD 1.000231
BTN 94.44641
BWP 14.015512
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42537
CDF 2315.000184
CHF 0.837958
CLF 0.025469
CLP 1002.376741
CNY 6.67175
CNH 6.673395
COP 3319.97
CRC 449.312832
CUC 1
CUP 24.064952
CVE 100.149904
CZK 22.122964
DJF 178.554905
DKK 6.77912
DOP 60.996961
DZD 137.215041
EGP 53.460841
ERN 15
ETB 164.576405
EUR 0.906405
FJD 2.27435
FKP 0.756889
GBP 0.756398
GEL 2.590269
GGP 0.756889
GHS 11.724953
GIP 0.756889
GMD 74.000357
GNF 8883.748356
GTQ 7.646644
GYD 209.264655
HKD 7.84526
HNL 26.963306
HRK 6.831965
HTG 131.491813
HUF 330.867502
IDR 18235.4
ILS 3.216696
IMP 0.756889
INR 94.245498
IQD 1520.116116
IRR 1913737.498051
ISK 123.929951
JEP 0.756889
JMD 158.434254
JOD 0.709004
JPY 159.657496
KES 130.049851
KGS 87.435501
KHR 4080.00019
KMF 447.000297
KPW 900.00035
KRW 1335.484966
KWD 0.31147
KYD 0.835579
KZT 446.945163
LAK 22570.87132
LBP 89792.715562
LKR 333.505692
LRD 170.463102
LSL 16.951422
LTL 2.952741
LVL 0.60489
LYD 6.463464
MAD 9.936862
MDL 18.213816
MGA 4555.721867
MKD 55.830725
MMK 2100.274506
MNT 3605.662913
MOP 8.103688
MRU 40.552456
MUR 47.619801
MVR 15.400731
MWK 1738.739965
MXN 18.526497
MYR 4.086105
MZN 63.902977
NAD 16.951422
NGN 1343.570244
NIO 36.90298
NOK 10.16413
NPR 151.114437
NZD 1.808483
OMR 0.385095
PAB 1.000231
PEN 3.411802
PGK 4.575679
PHP 63.960117
PKR 277.274459
PLN 3.994115
PYG 6207.891986
QAR 3.64425
RON 4.851895
RSD 106.558993
RUB 82.765228
RWF 1483.467138
SAR 3.82571
SBD 8.097697
SCR 13.874904
SDG 601.490624
SEK 10.06572
SGD 1.287102
SHP 0.752984
SLE 23.050404
SLL 20969.503664
SOS 573.048487
SRD 37.490144
STD 20697.981008
STN 22.225246
SVC 8.773983
SYP 13002.000337
SZL 16.946523
THB 33.874985
TJS 9.249966
TMT 3.5
TND 3.008497
TOP 2.40776
TRY 50.346255
TTD 6.806368
TWD 32.891398
TZS 2655.145825
UAH 45.588969
UGX 4131.053487
UYU 40.541335
UZS 12057.876355
VES 912.87925
VND 25725.5
VUV 120.320092
WST 2.810586
XAF 594.562705
XAG 0.020459
XAU 0.00025782798
XCD 2.70255
XCG 1.807139
XDR 0.707052
XOF 594.562705
XPF 108.324971
YER 236.550281
ZAR 16.93755
ZMK 9001.216069
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.080549
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025

Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025

STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on Friday, March 14, 2025, and Applied DNA common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the commencement of market open that same day.

Text size:

Applied DNA common stock will continue to trade on The Nasdaq Capital Market under the symbol "APDN" following the reverse stock split, with a new CUSIP number of 03815U 508. The CUSIP number for the Company's book entry warrants will not change.

After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced from approximately 55.2 million to approximately 1.1 million. The total authorized number of shares will not be reduced. Proportional adjustments will be made to the number of shares of common stock issuable upon exercise or vesting of the Company's outstanding stock options, restricted stock units, and warrants, as well as the applicable exercise or conversion prices, and to the number of shares issuable under the Company's equity incentive plans and other existing agreements. No fractional shares will be issued in connection with the reverse stock split, and fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. There will be no change in the par value of $0.001 per share of the common stock as a result of the reverse stock split.

As previously disclosed, at an annual meeting of stockholders held on September 30, 2024, the Company's stockholders voted to approve a proposal granting the Company's Board of Directors the discretion to amend the Company's certificate of incorporation to effect a reverse stock split of the Company's common stock at a ratio of not less than 1-for-5 and not more than 1-for-50. The Company's Board of Directors approved a 1-for-50 reverse stock split on March 3, 2025. The reverse stock split is intended to bring the Company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Applied DNA's transfer agent, Equiniti Trust Company, will provide information to stockholders regarding their stock ownership following the reverse stock split. Stockholders holding their shares in book-entry form or through a bank, broker, or other nominee do not need to take any action in connection with the reverse stock split. Their accounts will be automatically adjusted to reflect the number of shares owned. Beneficial holders are encouraged to contact their bank, broker, or other nominee with any procedural questions.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA. The Company operates in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services.

Visit adnas.com for more information. Follow us on X and LinkedIn.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding the effective date of the reverse stock split and the trading of the common stock on a split-adjusted basis, the Company's belief that the reverse stock split will allow the Company to regain compliance with Nasdaq listing standards, the Company's belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation, and the potential to achieve that goal, and regarding the future success of its Linea DNA™ and Linea™ IVT platforms and future reductions in operating expenses. Actual results could differ materially from those projected due to the Company's history of net losses, limited financial resources, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and or Linea DNA platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms, the unknown amount of revenues and profits that will result from its TR8™ PGx testing service, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Report on Form 10-Q filed on February 13, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Applied DNA Sciences Contact:

Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]
Web: adnas.com

###

SOURCE: Applied DNA Sciences, Inc.



View the original press release on ACCESS Newswire

D.Johnson--TFWP